Form 4 for NMRA Neumora Therapeutics, Inc.
Accepted 2023-09-18 00:00:00 ET · period of report 2023-09-14 · accession 0001610717-23-000286 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-18 | 2023-09-14 | NMRA | Lenz Robert A. | Head of R, D | A - Grant | $0.00 | +352.9K | 352.9K | New | $0 |
| D | 2023-09-18 | 2023-09-14 | NMRA | Lenz Robert A. | Head of R, D | A - Grant | $0.00 | +502.9K | 502.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-14 | A | A | 352,941 | $0.00 | 352,941 | D | — | — | (F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on September 11 of each year, with the first 1/4th vesting on September 11, 2024. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-09-14 | A | A | 502,934 | $0.00 | 502,934 | D | $17.00 · — to 2033-09-13 | 502,934 Common Stock | (F2) 25% of the shares subject to the option vest on the first anniversary measured from September 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |